APP
ASND icon

Avantax Planning Partners’s Ascendis Pharma A/S ASND Stock Holding History

Avantax Planning Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$14K – 345
2018
Q3 		$14K Buy
+200
New +$13.8K ﹤0.01% 783
2018
Q2 		– Sell
-200
Closed -$13K – 328
2018
Q1 		$13K Buy
+200
New +$11.2K ﹤0.01% 929

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Avantax Planning Partners's ASND Position: Q4 2018 in Review

Avantax Planning Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2018, closing a stake of 200 shares — an estimated $14K sold.

Avantax Planning Partners first reported a position in ASND in Q1 2018 and held it in 2 quarters. The position peaked at $14K in Q3 2018. 103 funds tracked by Wall St. Rank hold ASND as of Q4 2018.

  • Avantax Planning Partners reported no remaining Ascendis Pharma A/S position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 200 Ascendis Pharma A/S shares in Q4 2018, an estimated $14K.
  • Avantax Planning Partners first reported a position in Ascendis Pharma A/S in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Ascendis Pharma A/S position peaked at $14K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.